Cargando…

Hydroxamic acid – A novel molecule for anticancer therapy

Hydroxamic acid is a potent moiety not only in the field of cancer therapy but also as a mutagenic agent. Among the various derivatives of hydroxamic acid, SAHA (Suberoylanilide Hydroxamic Acid) is considered as a potent anticancer agent. Scientists from the different corner synthesized different hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Dilipkumar, Saha, Supriyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401680/
https://www.ncbi.nlm.nih.gov/pubmed/22837956
http://dx.doi.org/10.4103/2231-4040.97281
_version_ 1782238632343502848
author Pal, Dilipkumar
Saha, Supriyo
author_facet Pal, Dilipkumar
Saha, Supriyo
author_sort Pal, Dilipkumar
collection PubMed
description Hydroxamic acid is a potent moiety not only in the field of cancer therapy but also as a mutagenic agent. Among the various derivatives of hydroxamic acid, SAHA (Suberoylanilide Hydroxamic Acid) is considered as a potent anticancer agent. Scientists from the different corner synthesized different hydroxamic acid moieties with some straight chain oxazole, thiadiazole, biphenyl moieties in the terminal position. Acetylation and deacetylation of histones of the core proteins of nucleosomes in chromatin play an important role in the regulation of gene expression. The level of acetylation of histones is established and maintained by two classes of enzymes, histone acetyltransferase and histone deacetylases, which have been identified as transcriptional coactivators and transcriptional corepressors, respectively. There is increasing evidence that aberrant histone acetylation has been linked to various malignant diseases. Great efforts are currently underway for the design of more potent and less toxic candidates for the treatment of cancer. In recent years, hydroxamic acid derivatives have attracted increasing attention for their potential as highly efficacious in combating various etiological factors associated with cancer. Our main intention to draw an attention is that this single functional moiety has not only fit in the receptor but also create a diversified activity.
format Online
Article
Text
id pubmed-3401680
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-34016802012-07-26 Hydroxamic acid – A novel molecule for anticancer therapy Pal, Dilipkumar Saha, Supriyo J Adv Pharm Technol Res Review Article Hydroxamic acid is a potent moiety not only in the field of cancer therapy but also as a mutagenic agent. Among the various derivatives of hydroxamic acid, SAHA (Suberoylanilide Hydroxamic Acid) is considered as a potent anticancer agent. Scientists from the different corner synthesized different hydroxamic acid moieties with some straight chain oxazole, thiadiazole, biphenyl moieties in the terminal position. Acetylation and deacetylation of histones of the core proteins of nucleosomes in chromatin play an important role in the regulation of gene expression. The level of acetylation of histones is established and maintained by two classes of enzymes, histone acetyltransferase and histone deacetylases, which have been identified as transcriptional coactivators and transcriptional corepressors, respectively. There is increasing evidence that aberrant histone acetylation has been linked to various malignant diseases. Great efforts are currently underway for the design of more potent and less toxic candidates for the treatment of cancer. In recent years, hydroxamic acid derivatives have attracted increasing attention for their potential as highly efficacious in combating various etiological factors associated with cancer. Our main intention to draw an attention is that this single functional moiety has not only fit in the receptor but also create a diversified activity. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3401680/ /pubmed/22837956 http://dx.doi.org/10.4103/2231-4040.97281 Text en Copyright: © Journal of Advanced Pharmaceutical Technology & Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Pal, Dilipkumar
Saha, Supriyo
Hydroxamic acid – A novel molecule for anticancer therapy
title Hydroxamic acid – A novel molecule for anticancer therapy
title_full Hydroxamic acid – A novel molecule for anticancer therapy
title_fullStr Hydroxamic acid – A novel molecule for anticancer therapy
title_full_unstemmed Hydroxamic acid – A novel molecule for anticancer therapy
title_short Hydroxamic acid – A novel molecule for anticancer therapy
title_sort hydroxamic acid – a novel molecule for anticancer therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401680/
https://www.ncbi.nlm.nih.gov/pubmed/22837956
http://dx.doi.org/10.4103/2231-4040.97281
work_keys_str_mv AT paldilipkumar hydroxamicacidanovelmoleculeforanticancertherapy
AT sahasupriyo hydroxamicacidanovelmoleculeforanticancertherapy